Wellington Management Group LLP Buys 217,810 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Wellington Management Group LLP lifted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 5.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,127,610 shares of the biotechnology company’s stock after purchasing an additional 217,810 shares during the quarter. Wellington Management Group LLP owned 4.40% of Sarepta Therapeutics worth $398,025,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Cary Street Partners Investment Advisory LLC raised its stake in shares of Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 154 shares during the period. Principal Securities Inc. purchased a new position in Sarepta Therapeutics during the fourth quarter worth about $26,000. CWM LLC grew its position in Sarepta Therapeutics by 178.7% during the fourth quarter. CWM LLC now owns 577 shares of the biotechnology company’s stock worth $56,000 after buying an additional 370 shares in the last quarter. Fifth Third Bancorp grew its position in Sarepta Therapeutics by 1,215.8% during the fourth quarter. Fifth Third Bancorp now owns 1,000 shares of the biotechnology company’s stock worth $96,000 after buying an additional 924 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new position in Sarepta Therapeutics during the fourth quarter worth about $165,000. 86.68% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, insider Dallan Murray sold 3,635 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total transaction of $508,900.00. Following the completion of the transaction, the insider now owns 18,125 shares of the company’s stock, valued at approximately $2,537,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 7.70% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

SRPT has been the subject of several recent analyst reports. Oppenheimer upgraded Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $180.00 target price for the company in a research report on Tuesday, May 14th. JPMorgan Chase & Co. reduced their target price on Sarepta Therapeutics from $177.00 to $175.00 and set an “overweight” rating for the company in a research report on Friday, May 3rd. Royal Bank of Canada reiterated a “sector perform” rating and issued a $142.00 price objective (down from $157.00) on shares of Sarepta Therapeutics in a report on Tuesday, May 28th. UBS Group upped their price objective on Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Finally, Evercore ISI upped their price objective on Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an “in-line” rating in a report on Tuesday, February 20th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $164.00.

Sarepta Therapeutics Trading Down 4.9 %

SRPT opened at $116.83 on Tuesday. The business has a 50 day simple moving average of $125.38 and a two-hundred day simple moving average of $118.71. The firm has a market capitalization of $11.04 billion, a price-to-earnings ratio of 1,062.09 and a beta of 0.96. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44. Sarepta Therapeutics, Inc. has a one year low of $55.25 and a one year high of $146.68.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.84. The business had revenue of $413.50 million during the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. Sarepta Therapeutics’s quarterly revenue was up 63.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.44) EPS. Analysts predict that Sarepta Therapeutics, Inc. will post 2.99 EPS for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.